Characteristic pathological findings and effects of ecabet sodium in rat reflux esophagitis

World Journal of Gastroenterology

Volumn 15, Issue 28, 2009, Pages 3480-3485

  Asaoka, Daisuke ^a   Nagahara, Akihito ^a   Oguro, Masako ^a   Izumi, Yuko ^a   Kurosawa, Akihiko ^a   Osada, Taro ^a   Kawabe, Masato ^a   Hojo, Mariko ^a   Otaka, Michiro ^a   Watanabe, Sumio ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Extraesophageal syndrome; Gastroesophageal reflux disease; Laryngopharyngeal reflux disease; Upper esophagus

Indexed keywords

12 SULFODEHYDROABIETIC ACID; ABIETANE DERIVATIVE; ANTIULCER AGENT; ECABET;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL INFILTRATION; CONTROLLED STUDY; EPITHELIOID CELL; ESOPHAGUS; ESOPHAGUS ULCER; HISTOPATHOLOGY; HYPOPHARYNX; INCIDENCE; LEUKOCYTE; MALE; MUCOSA; NONHUMAN; POSTOPERATIVE PERIOD; RAT; REFLUX ESOPHAGITIS; SURVIVAL RATE; ANIMAL; DISEASE MODEL; HUMAN; IMMUNOLOGY; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTI-ULCER AGENTS; DISEASE MODELS, ANIMAL; DITERPENES, ABIETANE; ESOPHAGITIS, PEPTIC; ESOPHAGUS; HUMANS; LEUKOCYTES; MALE; RATS; RATS, WISTAR;

EID: 70349577931     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.3480     Document Type: Article

References (24)

1. Fujimoto K. Review article: prevalence and epidemiology of gastro-oesophageal reflux disease in Japan. Aliment Pharmacol Ther 2004; 20 Suppl 8: 5-8
2. Watanabe S, Hojo M, Nagahara A. Metabolic syndrome and gastrointestinal diseases. J Gastroenterol 2007; 42: 267-274
3. Dimenäs E. Methodological aspects of evaluation of Quality of Life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl 1993; 199: 18-21
4. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-1920; quiz 1943
5. Cherry J, Margulies SI. Contact ulcer of the larynx. Laryngoscope 1968; 78: 1937-1940
6. Richter JE. Review article: extraoesophageal manifestations of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 22 Suppl 1: 70-80
7. Orlando RC. Review article: oesophageal mucosal resistance. Aliment Pharmacol Ther 1998; 12: 191-197
8. Asaoka D, Miwa H, Hirai S, Ohkawa A, Kurosawa A, Kawabe M, Hojo M, Nagahara A, Minoo T, Ohkura R, Ohkusa T, Sato N. Altered localization and expression of tight-junction proteins in a rat model with chronic acid reflux esophagitis. J Gastroenterol 2005; 40: 781-790
9. Omura N, Kashiwagi H, Chen G, Suzuki Y, Yano F, Aoki T. Establishment of surgically induced chronic acid reflux esophagitis in rats. Scand J Gastroenterol 1999; 34: 948-953
10. Nagahama K, Yamato M, Nishio H, Takeuchi K. Essential role of pepsin in pathogenesis of acid reflux esophagitis in rats. Dig Dis Sci 2006; 51: 303-309
11. Okuyama K, Saito N, Kume E, Noto T, Nagasaki M. Ecabet sodium prevents esophageal lesions induced by the reflux of gastric juice in rats. Inflammopharmacology 2007; 15: 90-94
12. Takubo K, Honma N, Aryal G, Sawabe M, Arai T, Tanaka Y, Mafune K, Iwakiri K. Is there a set of histologic changes that are invariably reflux associated? Arch Pathol Lab Med 2005; 129: 159-163
13. Hongo M. Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol 2006; 41: 95-99
14. Collins BJ, Elliott H, Sloan JM, McFarland RJ, Love AH. Oesophageal histology in reflux oesophagitis. J Clin Pathol 1985; 38: 1265-1272
15. Yasunaga Y, Shinomura Y, Kanayama S, Higashimoto Y, Yabu M, Miyazaki Y, Kondo S, Murayama Y, Nishibayashi H, Kitamura S, Matsuzawa Y. Increased production of interleukin 1 beta and hepatocyte growth factor may contribute to foveolar hyperplasia in enlarged fold gastritis. Gut 1996; 39: 787-794
16. Vieth M, Kulig M, Leodolter A, Nauclér E, Jaspersen D, Labenz J, Meyer-Sabellek W, Lind T, Willich S, Malfertheiner P, Stolte M. Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus. Aliment Pharmacol Ther 2006; 23: 313-319
17. Tobey NA, Hosseini SS, Argote CM, Dobrucali AM, Awayda MS, Orlando RC. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol 2004; 99: 13-22
18. van Malenstein H, Farré R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol 2008; 103: 1021-1028
19. Tokashiki R, Nakamura K, Watanabe Y, Yamaguchi H, Suzuki M. The relationship between esophagoscopic findings and total acid reflux time below pH 4 and pH 5 in the upper esophagus in patients with laryngopharyngeal reflux disease (LPRD). Auris Nasus Larynx 2005; 32: 265-268
20. Kinoshita M, Endo M, Yasoshima A, Saito N, Yamasaki K, Chishima S, Narita H. Ecabet sodium, a novel locally-acting anti-ulcer agent, protects the integrity of the gastric mucosal gel layer from pepsin-induced disruption in the rat. Aliment Pharmacol Ther 1999; 13: 687-694
21. Ito Y, Nakamura S, Onoda Y, Sugawara Y, Takaiti O. Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. I. Inactivation of enzyme protein. Jpn J Pharmacol 1993; 62: 169-174
22. Pearson JP, Roberts NB. Mucosal protective effects of ecabet sodium: pepsin inhibition and interaction with mucus. Clin Sci (Lond) 2001; 100: 411-417
23. Furukawa O, Kume E, Sugamoto S, Kawauchi S, Takeuchi K. Effect of ecabet disodium, a novel locally-acting antiulcer drug, on epithelial restitution following injury by hypertonic NaCl in bullfrog stomach in vitro. Digestion 2000; 62: 116-125
24. Kinoshita M, Yamasaki K, Kokusenya Y, Tamaki H. Relationship between gastroprotective effect of locally acting antiulcer agent ecabet sodium and its binding to gastric mucosa in rats. Comparison with sucralfate. Dig Dis Sci 1995; 40: 661-667